Exposing The Truth About Peptides
A physician host walks through how an FDA advisory committee voted on seven popular peptides, and why he says the vote was not driven by new evidence.
Key moments
Tap a moment to play the video from there.
- 0:00Why peptides are everywhereDoctor Mike says patients keep asking about peptides and previews a story about a recent FDA committee vote on seven of them.
- 0:31What peptides are and aren'tHe describes peptides as short amino acid chains that act as messengers in the body, and uses insulin as a well-studied, regulated example.
- 2:07From bodybuilders to gray marketHe traces peptide use from bodybuilders and biohackers to clinics, med spas and websites selling research chemicals, and says many products were unregulated and self-injected.
- 5:43RFK and the compounding reviewHe says Kennedy, who has said he uses peptides, encouraged a new review by the committee that advises the FDA on compounded drugs.
- 6:46What the bulks list meansHe explains the 503A bulks list and the four questions used to judge a substance, and stresses that being listed is not FDA approval.
- 8:50What FDA scientists foundHe reports that the agency found little or no human data for BPC-157, KPV, TB-500 and MOTS-c, and raised purity and consistency concerns.
- 11:54The harm reduction argumentHe presents the pro-peptide case that people already buy these products anyway, and says it is logical but not what the approval process is designed to answer.
- 13:26The committee votesHe walks through the votes, saying six of seven peptides were recommended despite the scientists recommending against all of them, and notes the vote is only advisory.
- 14:27Who was votingHe says eight of 11 regular members were newly appointed, some with reported clinic or compounding ties, and that all yes votes came from them.
- 17:32A shortcut around trialsHe argues the process could let demand stand in for proof, but acknowledges some peptides could eventually become useful medicines.
What the video says
Doctor Mike opens by saying patients, friends and family keep asking him about peptides. He defines them as short chains of amino acids that act as chemical messengers, uses insulin as an example of a peptide that went through full regulatory review, and then traces how newer "wellness" peptides spread from bodybuilders to biohackers, celebrities, clinics, and gray market websites selling them as research chemicals.
The core of the video is a recent meeting of the FDA's compounding advisory committee, which was asked whether seven peptides should go on the 503A bulks list. He explains that this list governs which raw substances compounding pharmacies may legally use, and that being on it is not FDA approval. According to him, FDA scientists reviewed each peptide and recommended against all seven. He says that for BPC-157 they found one small meeting abstract involving 53 people and no randomized human trials for tendon, ligament or muscle use, and that for KPV, TB-500 and MOTS-c they could not identify human exposure data. He also raises manufacturing and purity questions.
He then describes the meeting itself. Supporters argued for harm reduction, saying people already buy these products from unregulated sources, and he calls that argument fairly logical while saying it does not answer the questions approval is meant to answer. The committee went on to recommend six of the seven peptides against the scientists' advice. He stresses this is advisory and does not make any peptide FDA-approved or declared safe.
The last section is his criticism of how the vote happened. He says eight of the 11 regular voting members had just started their terms, that several had reported ties to clinics or compounding businesses, and that every yes vote came from that group. He argues this could become a shortcut where consumer demand replaces trials, while allowing that some peptides may someday become useful medicines.
On each compound
BPC-1578:50
Doctor Mike says the FDA found only one small meeting abstract, 53 people and an enema route, for ulcerative colitis, and no randomized human trials for tendon, ligament or muscle recovery. He says the committee still voted 8 yes, 6 no and 1 abstention to recommend it.
See how your DNA reads BPC-157TB-5008:50
According to Doctor Mike, the FDA could not identify human exposure data for TB-500. He also cites a clip in which a speaker says exact sequences can vary between vendors, and says the committee recommended it with the same eight supporting votes.
See how your DNA reads TB-500KPV8:50
Doctor Mike says the FDA could not identify human exposure data for KPV, which was reviewed for wound healing and inflammatory conditions. He says it received the same eight supporting votes as BPC-157.
See how your DNA reads KPVMOTS-c8:00
Doctor Mike says MOTS-c was reviewed for obesity and osteoporosis and that the FDA could not identify human exposure data for it. He says it narrowly passed the committee vote.
See how your DNA reads MOTS-c“All seven peptides got no recommendations.”
What this video doesn’t settle
- The video does not review the underlying studies itself, so the FDA findings on BPC-157, TB-500, KPV and MOTS-c are reported secondhand from the host.
- It does not say whether any of the peptides work or are safe, only that the evidence the FDA reviewed was limited.
- The claims about member conflicts of interest rely on the host's summary of reports and a few clips, with no responses from the members shown.
Questions this video answers
Is BPC-157 FDA approved?
Doctor Mike says no. He explains that the committee vote was only advisory and that adding a substance to the 503A bulks list would still require formal government action. He calls claims that BPC-157 is FDA-approved or declared safe false.
What did FDA scientists find about BPC-157 and TB-500?
Doctor Mike reports that for BPC-157 they found one small meeting abstract of 53 people using an enema, and no randomized human trials for tendon, ligament or muscle recovery. For TB-500 he says they could not identify human exposure data.
What is the 503A bulks list?
According to Doctor Mike, it lists the raw substances compounding pharmacies are legally allowed to use to make customized medications for patients. He stresses that being on it is not the same as FDA approval for everybody.
Why did the peptide advisory committee vote differently from FDA scientists?
Doctor Mike says eight of the 11 regular voting members had just begun their terms, and that several reportedly had ties to clinics or compounding businesses. He says every yes vote came from those new members, while every longer-serving expert voted no or abstained.
What is the harm reduction argument for compounded peptides?
Doctor Mike says supporters argued that Americans already buy and inject peptides from overseas sellers and research chemical sites. They said a licensed pharmacy source may be less risky than an unregulated one, and he calls this fairly logical while noting it is a different question from efficacy and safety.
Video by Doctor Mike on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
